Q1: 2026-05-07 Earnings Summary
EPS of $0.13 misses by $0.06
| Revenue of $893.65M (25.52% Y/Y) beats by $3.01M
Genmab A/S (GMAB) Q1 2026 Earnings Call May 7, 2026 12:00 PM EDT
Company Participants
Jan van de Winkel – Co-Founder, President & CEO
Brad Bailey – Executive VP & Chief Commercial Officer
Anthony Pagano – Executive VP & CFO
Tahamtan Ahmadi – Executive VP, Chief Medical Officer & Head of Experimental Medicines
Judith Klimovsky – Executive VP & Chief Development Officer
Conference Call Participants
Jonathan Chang – Leerink Partners LLC, Research Division
Zain Ebrahim – JPMorgan Chase & Co, Research Division
James Gordon – Barclays Bank PLC, Research Division
Xian Deng – UBS Investment Bank, Research Division
Rajan Sharma – Goldman Sachs Group, Inc., Research Division
Michael Schmidt – Guggenheim Securities, LLC, Research Division
Benjamin Jackson – Jefferies LLC, Research Division
Charlie Haywood – BofA Securities, Research Division
Eva Fortea-Verdejo – Wells Fargo Securities, LLC, Research Division
Matthew Phipps – William Blair & Company L.L.C., Research Division
Yaron Werber – TD Cowen, Research Division
Romy O’Connor – Van Lanschot Kempen NV
Victor Floch – BNP Paribas, Research Division
Kalpit Patel – Wolfe Research, LLC
Judah Frommer – Morgan Stanley, Research Division
Presentation
Operator
Hello, and welcome to the Genmab First Quarter 2026 Financial Results Conference Call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects.
Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as a part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.
